Knockdown of RhoGDI2 Represses Human Gastric Cancer Cell Proliferation, Invasion and Drug Resistance Via the Rac1/Pak1/LIMK1 Pathway.

Ying Zeng,Mei Ren,Yukun Li,Yanli Liu,Cong Chen,Jian Su,Bo Su,Hong Xia,Fang Liu,Hao Jiang,Hui Ling,Xi Zeng,Qi Su
DOI: https://doi.org/10.1016/j.canlet.2020.07.013
IF: 9.756
2020-01-01
Cancer Letters
Abstract:Gastric cancer (GC) is the fifth most common primary malignancy in humans. Rho GDP dissociation inhibitor 2 (RhoGDI2) is overexpressed in multiple cancer types, but the role of RhoGDI2 in GC has not been elucidated. This study aims to determine the level of RhoGDI2 in GC and to confirm the effect of its inhibition or overexpression on GC cell migration, invasion and chemosensitivity. RhoGDI2 level is significantly enhanced in human GC tissue samples in comparison with normal gastric epithelium and corresponding para-cancerous samples. The expression of RhoGDI2 is correlated with clinicopathological parameters and prognosis. Transfection in combination with miRNA targeting of RhoGDI2 in GC cell lines remarkably downregulates GC cell migration and invasion and reduces the mRNA levels of Rac1, Pak1 and LIMK1. The inhibition of RhoGDI2 downregulates GC cell migration and invasion by attenuating the EMT cascade via the Rac1/Pak1/LIMK1 pathway. Knockdown of RhoGDI2 is a potential therapeutic strategy for GC.
What problem does this paper attempt to address?